More recently, HER2 has also been established as an important target in multiple cancers, including gastric, ovarian, pancreatic, and kidney cancers as a consequence of its gene amplification or the presence of somatic mutations, driving HER2 activation and tumor aggressiveness [8, 9]. Here, ERBB2 is linked to neoplasm.